Brii Biosciences Reports Mixed Mid-Year Financials

Brii Biosciences Limited (HK:2137) has released an update.

Brii Biosciences Limited reported a decrease in cash reserves and other income for the first half of 2024, alongside reduced expenses in research and development, as well as administrative costs due to strategic pipeline prioritization and organizational optimization. However, the company experienced a significant increase in net loss, largely due to fair value losses on financial assets, despite the cost-saving measures.

For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.